Imagion Biosystems receives $300K order for supply of nanoparticles

Nov 27, 2019
Posted in: News, Investor updates

Home » Imagion Biosystems receives $300K order for supply of nanoparticles

Imagion Biosystems receives $300K order for supply of nanoparticles

Nov 27, 2019
Posted in: News, Investor updates

Imagion Biosystems Limited announced the NewPhase Ltd., an Israeli biotechnology company developing cancer treatments, has placed an order totaling approximately $300k for the supply of Imagion’s proprietary nanoparticles for 2020 to be used in the NewPhase product.
Read the announcement.

Imagion Biosystems receives AU$3.5 million in R&D tax incentives

September 19, 2023

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it

1H2023 Half-Year Results

August 30, 2023

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing Early Pancreatic Cancer Diagnosis Platform

August 11, 2023

SINGAPORE, and San Diego, California – Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Imagion Biosystems receives $300K order for supply of nanoparticles

Imagion Biosystems receives $300K order for supply of nanoparticles

Related Articles

Imagion Biosystems receives AU$3.5 million in R&D tax incentives

1H2023 Half-Year Results

Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing Early Pancreatic Cancer Diagnosis Platform

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list